ZIELBIO
ZielBio is an early-stage biotechnology company that identifies novel high-value disease targets and develops therapeutic interventions to improve patient outcomes. Its proprietary drug discovery platform Zielfind combines the power of functional, high throughput screening with large content data analytics to identify high-value targets. They have a promising pipeline of therapies and targets, including lead compound ZB131, a proprietary humanized monoclonal antibody against cell surface plectin (CSP) a cancer target identified through Zielfind. ZielBio was founded in 2011 and is based in Charlottesville, Virginia, United States.
ZIELBIO
Industry:
Biotechnology Health Care Therapeutics
Founded:
2011-01-01
Address:
Charlottesville, Virginia, United States
Country:
United States
Website Url:
http://www.zielbio.com
Total Employee:
1+
Status:
Active
Contact:
(434) 202-7771
Total Funding:
25.55 M USD
Similar Organizations
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
Current Advisors List
Current Employees Featured
Founder
Investors List
Morningside Venture Investments
Morningside Venture Investments investment in Series A - ZielBio
Partners Innovation Fund
Partners Innovation Fund investment in Series A - ZielBio
Key Employee Changes
| Date | New article |
|---|---|
| 2020-12-09 | ZielBio Appoints Dieter Weinand Executive Chair as Company Heads Toward the Clinic with Lead Oncology Therapeutic |
